Inside Kyron.bio’s Bold Bet to Rewrite the Rules of Antibody Drug Design
For all the buzz around antibody therapies, one overlooked culprit keeps holding them back: sugars. Paris-based Kyron.bio is tackling the hidden complexity of glycosylation — the way sugars attach to therapeutic proteins — with a platform that promises safer, longer-lasting drugs.
Latest
🇫🇷 French Tech Wire: French VC In 2026 Gets Bigger, Riskier, and Less Forgiving
From a quiet AI MarTech exit and a fallen French Tech icon to climate bets, double-centaur milestones, and fintech credit consolidation, this week’s Wire tracks how French startups scale, stumble, and adapt in a tougher capital cycle.
French VC Outlook 2026: More concentration, Fewer Bets, Bigger Stakes
As the new year kicks off, we’re once again asking French VCs to peer into the crystal ball and tell us what they see on the horizon. Spoiler alert: the fog hasn’t entirely lifted, but patterns are starting to emerge.
🤖 La Machine #59: Voice AI Is Wild, Weird, and Wonderfully Investable
From AI bands and synthetic voices to serious money and real power, Voice AI is changing art, culture, and business. We dive into the fast-growing audio AI scene, including France's ecosystem, where creativity, capital, and controversy collide.
🐇 Follow Me Down The Voice AI Rabbit Hole 🎤
Voice AI has crossed the uncanny valley, turning sound, speech, and music into powerful tools. It’s fun, unsettling, and wildly investable. Welcome to the hottest, weirdest market in AI, where France is making some noise.